Semax
Semax is a militarized neuro-stimulatory heptapeptide derived from a fragment of Adrenocorticotropic Hormone (ACTH). Engineered to maintain operational clarity under severe hypoxia and extreme stress, it stands as one of the most rigorously validated nootropics globally. Administered intranasally for virtually instantaneous blood-brain barrier penetration, Semax aggressively sharpens focus, accelerates complex problem-solving velocity, and provides massive neuroprotection against stroke-induced oxidative damage.
Quick Stats
Scientific Data
Mechanism of Action
Semax is a synthetic heptapeptide analog of ACTH (adrenocorticotropic hormone), specifically the ACTH(4-10) fragment with additional stabilizing modifications. It has neuroprotective and cognitive-enhancing properties. Semax increases BDNF and NGF (Nerve Growth Factor) expression, modulates the serotonergic system, and provides neuroprotection against oxidative stress.
Like Selank, Semax is approved in Russia as a prescription medication — specifically for stroke recovery, cognitive disorders, and optic nerve diseases. It is primarily administered intranasally due to its very short systemic half-life (~2-3 minutes).
Source: PMID: 17430556
Background & History
Semax is a synthetic heptapeptide derived from the ACTH(4-7) fragment (Met-Glu-His-Phe), with Pro-Gly-Pro added for stability, developed at the Institute of Molecular Genetics (Moscow) in the 1980s. It is approved in Russia for stroke rehabilitation, TBI, and optic nerve disease, with clinical use spanning 30+ years. Its primary mechanism involves upregulation of BDNF and NGF — the most important neurotrophic proteins for synaptic plasticity, neuronal survival, and cognitive function — placing it uniquely in the landscape of genuine nootropics with clinical validation.
Research Use Cases
- ✓Stroke rehabilitation and post-TBI neurological recovery
- ✓ADHD-like symptoms: focus, attention, and executive function
- ✓Nootropic: memory formation and recall enhancement
- ✓Optic nerve disease treatment (Russian clinical use)
- ✓Depression adjunct via BDNF upregulation
Dosing Protocol
| Typical Dose | 200-600 mcg/day (intranasal) |
| Frequency | 1-3× daily (intranasal) |
| Half-Life | ~2-3 minutes (rapid metabolism) |
| Common Vial Sizes | 3 mg, 5 mg |
Dosing Protocols
Standard Protocol
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 200–600 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 154 mcg | 309 mcg | 463 mcg |
| 140 lb(63 kg) | 180 mcg | 360 mcg | 540 mcg |
| 160 lb(73 kg) | 209 mcg | 417 mcg | 626 mcg |
| 180 lb(82 kg) | 234 mcg | 469 mcg | 703 mcg |
| 200 lb(91 kg) | 260 mcg | 520 mcg | 780 mcg |
| 220 lb(100 kg) | 286 mcg | 571 mcg | 857 mcg |
| 250 lb(113 kg) | 323 mcg | 646 mcg | 969 mcg |
💉 For exact syringe units based on your vial concentration, use the Semax Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Neuroprotection / Stroke Recovery
HighApproved in Russia for stroke recovery. BDNF and NGF upregulation supports neuronal repair.
Cognitive Enhancement / Nootropic
HighDoes not affect cortisol despite ACTH origin. Well-tolerated cognitive booster.
Reconstitution Example
Safety & Considerations
Approved in Russia for stroke recovery and cognitive disorders. Good clinical safety profile. Does not affect cortisol. Primary route is intranasal.
Regulatory & Legal Status
Approved in Russia as a nasal spray; not FDA-approved
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Intranasal route required for adequate CNS bioavailability (nasal mucosa→olfactory neurons). ACTH-like structure may weakly affect cortisol — monitor with prolonged high-dose use. No significant drug interactions documented. Avoid in patients with active epilepsy (CNS stimulation theoretically could lower threshold).
Synergies & Common Stacks
Classic Russian nootropic stack: Semax enhances cognitive performance; Selank reduces performance anxiety. Together they support both cognitive output and emotional stability.
Semax provides the BDNF; Dihexa promotes the synaptogenesis to utilize it. Potentially powerful combination for neurological recovery or enhancement.
Semax vs. Selank
| Attribute | Semax | Selank |
|---|---|---|
| Primary Effect | Stimulating cognitive enhancer | Calming anxiolytic |
| BDNF Impact | Strong BDNF upregulation | Mild BDNF impact |
| Mood Effect | Energising / drive / motivation | Anti-anxiety / calm focus |
| Timing | Best AM use | Best PM or high-stress use |
| Approval | Russia (Semax nasal spray) | Russia (Selank nasal spray) |
Verdict: Semax is the stimulating neuropeptide for cognitive performance and BDNF-driven neuroplasticity. Selank is the calming partner. Together they offer a full-spectrum nootropic from two directions.
Dosing Quick Reference
Frequently Asked Questions
Does Semax affect cortisol like ACTH?▼
What is the Semax dosing protocol?▼
References
- Dolotov OV et al. “"Neuroprotective effects of the synthetic ACTH analogue Semax".” Journal of Neurochemistry (2006). PMID: 16978359
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code